柳氮磺吡啶联合来氟米特治疗强直性脊柱炎的临床分析

Clinical Analysis of Salazosulfapyridine Combined with Leflunomide in Treatment of Spondylitis Ankylopoietica

目的对强直性脊柱炎应用柳氮磺吡啶与来氟米特联合治疗的效果进行探讨。方法选取该院2014年6月—2017年6月期间收治的强直性脊柱炎患者116例进行研究,按照随机原则分为观察组(n=58)与对照组(n=58),对照组采用柳氮磺吡啶治疗,观察组在对照组用药基础上增加来氟米特治疗,对两组患者治疗有效率、不良反应及6个月后关节疼痛感数量、晨僵、红细胞沉降率、扩胸试验及C反应蛋白等指标进行对比。结果治疗总有效率方面,观察组(94.83%)明显高于对照组(77.59%),差异有统计学意义(χ~2=9.196,P<0.05);治疗6个月后,观察组晨僵为(13.14±9.32)s、关节疼痛数为(0.90±0.11)个、扩胸试验疼痛指数(2.23±0.82)、红细胞沉降率(14.57±5.29)mm/h、C反应蛋白为(8.61±5.52)mg/L,对照晨僵为(19.27±8.74)s、关节疼痛数为(1.58±0.14)个、扩胸试验疼痛指数(3.96±0.83)、红细胞沉降率(24.35±4.46)mm/h、C反应蛋白为(15.22±4.97)mg/L,观察组各指标均低于对照组,差异有统计学意义(t=3.782、3.655、4.623、4.182、3.953,P<0.05);不良反应方面,观察组为15.52%,对照组为12.07%,两组对比差异无统计学意义(χ~2=1.037,P>0.05)。结论对强直性脊柱炎患者采用柳氮磺吡啶联合来氟米特进行治疗,对患者病情具有较好的缓解作用,治疗效果显著,用药安全可靠,在临床中有推广应用的价值。

Objective To study the effect of salazosulfapyridine combined with leflunomide in treatment of spondylitis ankylopoietica. Methods 116 cases of patients with spondylitis ankylopoietica admitted and treated in our hospital from June 2014 to June 2017 were selected and randomly divided into two groups with 58 cases in each, the control group were treated with salazosulfapyridine, while the observation group were treated with salazosulfapyridine combined with leflunomide, and the treatment effective rate, adverse reactions, joint pain number after 6 months, morning stiffness and erythrocyte sedimentation rate, chest spreader and C reactive protein were compared between the two groups. Results The total treatment effective in the observation group was obviously higher than that in the control group（94.83% vs77.59%）, and the difference was statistically significant（χ~2=9.196, P 0.05）, after 6 months, the morning stiffness, joint pain number, chest spreader pain index, erythrocyte sedimentation rate, and C reactive protein in the observation group were lower than those in the control group, [（13.14±9.32） s,（0.90±0.11）,（2.23±0.82）,（14.57±5.29） mm/h,（8.61±5.52） mg/L vs（19.27±8.74） s,（1.58±0.14）,（3.96±0.83）,（24.35±4.46） mm/h,（15.22±4.97） mg/L], and the differences were statistically significant（t=3.782, 3.655, 4.623, 4.182, 3.953, P 0.05）, and the incidence rate of adverse reactions in the observation group and in the control group was respectively 15.52% and 12.07%, and the difference between the two groups was not statistically significant（χ~2=1.037, P 0.05）. Conclusion The sulfasalazine combined with leflunomide in treatment of spondylitis ankylopoietica can better relieve the disease conditions of patients, and the treatment effect is obvious, and the medication is safe and reliable, and it is of promotion and application value.